|
1
|
Pignata S, Cannella L, Leopardo D, Pisano
C, Bruni GS and Facchini G: Chemotherapy in epithelial ovarian
cancer. Cancer Lett. 303:73–83. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Khaider NG, Lane D, Matte I, Rancourt C
and Piché A: Targeted ovarian cancer treatment: The TRAILs of
resistance. Am J Cancer Res. 2:75–92. 2012.PubMed/NCBI
|
|
3
|
Kigawa J: New strategy for overcoming
resistance to chemotherapy of ovarian cancer. Yonago Acta Med.
56:43–50. 2013.PubMed/NCBI
|
|
4
|
Saei AA and Omidi Y: A glance at DNA
microarray technology and applications. Bioimpacts. 1:75–86.
2011.PubMed/NCBI
|
|
5
|
Cao WJ, Wu HL, He BS, Zhang YS and Zhang
ZY: Analysis of long non-coding RNA expression profiles in gastric
cancer. World J Gastroenterol. 19:3658–3664. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Qu C, Liang Z, Huang J, Zhao R, Su C, Wang
S, Wang X, Zhang R, Lee MH and Yang H: MiR-205 determines the
radioresistance of human nasopharyngeal carcinoma by directly
targeting PTEN. Cell Cycle. 11:785–796. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huh JH, Kim TH, Kim K, Song JA, Jung YJ,
Jeong JY, Lee MJ, Kim YK, Lee DH and An HJ: Dysregulation of
miR-106a and miR-591 confers paclitaxel resistance to ovarian
cancer. Br J Cancer. 109:452–461. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Park YT, Jeong JY, Lee MJ, Kim KI, Kim TH,
Kwon YD, Lee C, Kim OJ and An HJ: MicroRNAs overexpressed in
ovarian ALDH1-positive cells are associated with chemoresistance. J
Ovarian Res. 6:182013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Katagiri A, Nakayama K, Rahman MT, Rahman
M, Katagiri H, Nakayama N, Ishikawa M, Ishibashi T, Iida K,
Kobayashi H, et al: Loss of ARID1A expression is related to shorter
progression-free survival and chemoresistance in ovarian clear cell
carcinoma. Mod Pathol. 25:282–288. 2012.PubMed/NCBI
|
|
10
|
Rahman MT, Nakayama K, Rahman M, Katagiri
H, Katagiri A, Ishibashi T, Ishikawa M, Iida K, Nakayama S, Otsuki
Y and Miyazaki K: Notch3 overexpression as potential therapeutic
target in advanced stage chemoresistant ovarian cancer. Am J Clin
Pathol. 138:535–544. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vecchione A, Belletti B, Lovat F, Volinia
S, Chiappetta G, Giglio S, Sonego M, Cirombella R, Onesti EC,
Pellegrini P, et al: A microRNA signature defines chemoresistance
in ovarian cancer through modulation of angiogenesis. Proc Natl
Acad Sci USA. 110:9845–9850. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, Holko M, et al: NCBI GEO: Archive for functional
genomics data sets-update. Nucleic Acids Res. 41:D991–D995. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Garcia DM, Baek D, Shin C, Bell GW,
Grimson A and Bartel DP: Weak seed-pairing stability and high
target-site abundance decrease the proficiency of lsy-6 and other
microRNAs. Nat Struct Mol Biol. 18:1139–1146. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Grimson A, Farh KK, Johnston WK,
GarrettEngele P, Lim LP and Bartel DP: MicroRNA targeting
specificity in mammals: Determinants beyond seed pairing. Mol Cell.
27:91–105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Snel B, Lehmann G, Bork P and Huynen MA:
STRING: A web-server to retrieve and display the repeatedly
occurring neighbourhood of a gene. Nucleic Acids Res. 28:3442–3444.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Szklarczyk D, Franceschini A, Kuhn M,
Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork
P, et al: The STRING database in 2011: Functional interaction
networks of proteins, globally integrated and scored. Nucleic Acids
Res. 39:D561–D568. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Franceschini A, Szklarczyk D, Frankild S,
Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C
and Jensen LJ: STRING v9.1: Protein-protein interaction networks,
with increased coverage and integration. Nucleic Acids Res.
41:D808–D815. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
TabasMadrid D, NogalesCadenas R and
Pascual-Montano A: GeneCodis3: A non-redundant and modular
enrichment analysis tool for functional genomics. Nucleic Acids
Res. 40:W478–W483. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
NogalesCadenas R, CarmonaSaez P, Vazquez
M, Vicente C, Yang X, Tirado F, Carazo JM and Pascual-Montano A:
GeneCodis: Interpreting gene lists through enrichment analysis and
integration of diverse biological information. Nucleic Acids Res.
37:W317–W322. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Iwaya T, Fukagawa T, Suzuki Y, Takahashi
Y, Sawada G, Ishibashi M, Kurashige J, Sudo T, Tanaka F, Shibata K,
et al: Contrasting expression patterns of histone mRNA and microRNA
760 in patients with gastric cancer. Clin Cancer Res. 19:6438–6449.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Q, Huang Z, Ni S, Xiao X, Xu Q, Wang
L, Huang D, Tan C, Sheng W and Du X: Plasma miR-601 and miR-760 are
novel biomarkers for the early detection of colorectal cancer. PLoS
One. 7:e443982012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zheng XH, Cui C, Ruan HL, Xue WQ, Zhang
SD, Hu YZ, Zhou XX and Jia WH: Plasma microRNA profiles of
nasopharyngeal carcinoma patients reveal miR-548q and miR-483-5p as
potential biomarkers. Chin J Cancer. 33:330–338. 2014.PubMed/NCBI
|
|
23
|
Wang L, Shi M, Hou S, Ding B, Liu L, Ji X,
Zhang J and Deng Y: MiR-483-5p suppresses the proliferation of
glioma cells via directly targeting ERK1. FEBS Lett. 586:1312–1317.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu X, Zhang X, Bi T, Ding Y, Zhao J, Wang
C, Jia T, Han D, Guo G, Wang B, et al: MiRNA expression signature
for potentially predicting the prognosis of ovarian serous
carcinoma. Tumour Biol. 34:3501–3508. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hummel R, Wang T, Watson DI, Michael MZ,
Van der Hoek M, Haier J and Hussey DJ: Chemotherapy-induced
modification of microRNA expression in esophageal cancer. Oncol
Rep. 26:1011–1017. 2011.PubMed/NCBI
|
|
26
|
Li X, Shi Y, Yin Z, Xue X and Zhou B: An
eight-miRNA signature as a potential biomarker for predicting
survival in lung adenocarcinoma. J Transl Med. 12:1592014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sand M, Skrygan M, Georgas D, Sand D, Hahn
SA, Gambichler T, Altmeyer P and Bechara FG: Microarray analysis of
microRNA expression in cutaneous squamous cell carcinoma. J
Dermatol Sci. 68:119–126. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Qi B, Yao WJ, Zhao BS, Qin XG, Wang Y,
Wang WJ, Wang TY, Liu SG and Li HC: Involvement of microRNA-198
overexpression in the poor prognosis of esophageal cancer. Asian
Pac J Cancer Prev. 14:5073–5076. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Han HS, Yun J, Lim SN, Han JH, Lee KH, Kim
ST, Kang MH, Son SM, Lee YM, Choi SY, et al: Downregulation of
cell-free miR-198 as a diagnostic biomarker for lung
adenocarcinoma-associated malignant pleural effusion. Int J Cancer.
133:645–652. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tsai KW, Wu CW, Hu LY, Li SC, Liao YL, Lai
CH, Kao HW, Fang WL, Huang KH, Chan WC and Lin WC: Epigenetic
regulation of miR-34b and miR-129 expression in gastric cancer. Int
J Cancer. 129:2600–2610. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen X, Ruan A, Wang X, Han W, Wang R, Lou
N, Ruan H, Qiu B, Yang H and Zhang X: miR-129-3p, as a diagnostic
and prognostic biomarker for renal cell carcinoma, attenuates cell
migration and invasion via downregulating multiple
metastasis-related genes. J Cancer Res Clin Oncol. 140:1295–1304.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nordentoft I, BirkenkampDemtroder K,
Agerbaek M, Theodorescu D, Ostenfeld MS, Hartmann A, Borre M,
Ørntoft TF and Dyrskjøt L: miRNAs associated with chemo-sensitivity
in cell lines and in advanced bladder cancer. BMC Med Genomics.
5:402012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Amsterdam A, Shezen E, Raanan C, Schreiber
L, Prus D, Slilat Y, BenArie A and Seger R: Nuclear localization of
phosphorylated ERK1 and ERK2 as markers for the progression of
ovarian cancer. Int J Oncol. 39:649–656. 2011.PubMed/NCBI
|
|
34
|
Jeong EK, Lee SY, Jeon HM, Ju MK, Kim CH
and Kang HS: Role of extracellular signal-regulated kinase (ERK)
1/2 in multicellular resistance to docetaxel in MCF-7 cells. Int J
Oncol. 37:655–661. 2010.PubMed/NCBI
|
|
35
|
Guégan JP, Ezan F, Théret N, Langouët S
and Baffet G: MAPK signaling in cisplatin-induced death:
Predominant role of ERK1 over ERK2 in human hepatocellular
carcinoma cells. Carcinogenesis. 34:38–47. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang D, Li X, Yao Z, Wei C, Ning N and Li
J: GABAergic signaling facilitates breast cancer metastasis by
promoting ERK1/2-dependent phosphorylation. Cancer Lett.
348:100–108. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu YY, Ma TL, Ge ZJ, Lin J, Ding WL, Feng
JK, Zhou SJ, Chen GC, Tan YF and Cui GX: JWA gene regulates PANC-1
pancreatic cancer cell behaviors through MEK-ERK1/2 of the MAPK
signaling pathway. Oncol Lett. 8:1859–1863. 2014.PubMed/NCBI
|
|
38
|
Al Tassan N, Khalil D, Shinwari J, Al
Sharif L, Bavi P, Abduljaleel Z, Abu Dhaim N, Magrashi A, Bobis S,
Ahmed H, et al: A missense mutation in PIK3R5 gene in a family with
ataxia and oculomotor apraxia. Hum Mutat. 33:351–354. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shull AY, LathamSchwark A, Ramasamy P,
Leskoske K, Oroian D, Birtwistle MR and Buckhaults PJ: Novel
somatic mutations to PI3 K pathway genes in metastatic melanoma.
PLoS One. 7:e433692012. View Article : Google Scholar : PubMed/NCBI
|
